[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GR1008531B - Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη - Google Patents

Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη

Info

Publication number
GR1008531B
GR1008531B GR20140100157A GR20140100157A GR1008531B GR 1008531 B GR1008531 B GR 1008531B GR 20140100157 A GR20140100157 A GR 20140100157A GR 20140100157 A GR20140100157 A GR 20140100157A GR 1008531 B GR1008531 B GR 1008531B
Authority
GR
Greece
Prior art keywords
atomoxetine hydrochloride
oral solution
maltitol
xylitol
solutions
Prior art date
Application number
GR20140100157A
Other languages
English (en)
Inventor
Ηλιας Ιωαννη Κοτσιανης
Αργυρω Ευσταθιου Σταππα
Αγγελος Αντωνιου Καρατζας
Κωνσταντινος Αναστασιου Αποστολου
Original Assignee
Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε., filed Critical Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε.,
Priority to GR20140100157A priority Critical patent/GR1008531B/el
Priority to PCT/EP2014/059020 priority patent/WO2015144255A1/en
Priority to PL14726544T priority patent/PL3003384T3/pl
Priority to EP14726544.1A priority patent/EP3003384B1/en
Priority to PT147265441T priority patent/PT3003384T/pt
Priority to ES14726544.1T priority patent/ES2617252T3/es
Publication of GR1008531B publication Critical patent/GR1008531B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Πόσιμα υδατικά διαλύματα που περιέχουν υδροχλωρική ατομοξετίνη ως δραστικό συστατικό και έναν υγρό φορέα που περιέχει ξυλιτόλη, μαλτιτόλη και ένα γλυκαντικό που επιλέγεται από την ομάδα που αποτελείται από τη σουκραλόζη, τη σακχαρίνη, τη νατριούχα σακχαρίνη ή την ασβεστούχα σακχαρίνη, την στεβιοσίδη και την ρεμπαουδιοσίδη. Το pΗ του διαλύματος ρυθμίζεται στην περιοχή από 3.5 έως 4.5. Τα διαλύματα της παρούσας εφεύρεσης είναι εύγεστα, ακόμη και κατά την απουσία περαιτέρω πολυϋδρικών ή σακχαρούχων αλκοολών, πλέον της ξυλιτόλης και μαλτιτόλης.
GR20140100157A 2014-03-21 2014-03-21 Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη GR1008531B (el)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GR20140100157A GR1008531B (el) 2014-03-21 2014-03-21 Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη
PCT/EP2014/059020 WO2015144255A1 (en) 2014-03-21 2014-05-02 Oral solution comprising atomoxetine hydrochloride
PL14726544T PL3003384T3 (pl) 2014-03-21 2014-05-02 Roztwór doustny zawierający chlorowodorek atomoksetyny
EP14726544.1A EP3003384B1 (en) 2014-03-21 2014-05-02 Oral solution comprising atomoxetine hydrochloride
PT147265441T PT3003384T (pt) 2014-03-21 2014-05-02 Solução oral contendo cloridrato de atomoxetina
ES14726544.1T ES2617252T3 (es) 2014-03-21 2014-05-02 Solución oral que comprende clorhidrato de atomoxetina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20140100157A GR1008531B (el) 2014-03-21 2014-03-21 Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη

Publications (1)

Publication Number Publication Date
GR1008531B true GR1008531B (el) 2015-07-13

Family

ID=50828874

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20140100157A GR1008531B (el) 2014-03-21 2014-03-21 Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη

Country Status (6)

Country Link
EP (1) EP3003384B1 (el)
ES (1) ES2617252T3 (el)
GR (1) GR1008531B (el)
PL (1) PL3003384T3 (el)
PT (1) PT3003384T (el)
WO (1) WO2015144255A1 (el)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009883B (el) * 2019-06-07 2020-12-11 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105726473A (zh) * 2016-03-31 2016-07-06 北京万全德众医药生物技术有限公司 托莫西汀或其可药用盐口服溶液及其制备方法
CN106727291B (zh) * 2016-12-06 2020-02-11 山东达因海洋生物制药股份有限公司 一种盐酸托莫西汀口服溶液及其制备方法
US9855228B1 (en) 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof
CN112438949A (zh) * 2019-09-05 2021-03-05 北京兴源联合医药科技有限公司 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法
CN111956607A (zh) * 2020-09-25 2020-11-20 健民药业集团股份有限公司 盐酸托莫西汀口服溶液及其制备方法
CN115778895B (zh) * 2022-11-30 2024-04-26 江苏广承药业有限公司 一种盐酸托莫西汀口服溶液
WO2024156799A1 (en) * 2023-01-27 2024-08-02 Hyloris Developments Sa Use of vitamin e tpgs as a taste masking agent for bitter drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT73982B (en) 1980-11-14 1983-11-23 Lilly Co Eli Process for preparing 3-aryloxy-3-phenylpropylamines
JP2007517050A (ja) * 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
WO2006020348A2 (en) * 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
US10624372B2 (en) * 2009-08-28 2020-04-21 Symrise Ag Reduced-sweetener products, flavoring mixtures for said reduced-sweetener products and process for the production of products of this type

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009883B (el) * 2019-06-07 2020-12-11 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη

Also Published As

Publication number Publication date
EP3003384A1 (en) 2016-04-13
ES2617252T3 (es) 2017-06-16
WO2015144255A1 (en) 2015-10-01
PL3003384T3 (pl) 2017-06-30
PT3003384T (pt) 2017-01-18
EP3003384B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
GR1008531B (el) Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη
MY190296A (en) High intensity sweeteners
EA201792224A1 (ru) Композиции, содержащие ибрутиниб
AR097213A1 (es) Composiciones edulcorantes
UA105229C2 (uk) Фармацевтичний склад
MX2016007178A (es) Glucosidos de triterpeno novedosos como edulcorantes o potenciadores de edulcorantes.
UA107570C2 (xx) Безспиртовий водний розчин, що містить пропранолол
NZ588602A (en) Liquid formulation for deferiprone with palatable taste
MX2013010046A (es) Administracion parenteral de tapentadol.
MX2013008500A (es) Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
ZA202100339B (en) Sweetening compositions
MX365663B (es) Solucion de atomoxetina.
ITTO20120776A1 (it) Procedimento per mascherare l'amaro di un filtro uv
RU2016138577A (ru) Жидкая фармцевтическая композиция
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
MX346039B (es) Solucion farmaceutica bebible de telmisartan.
TR201909422T4 (tr) Flurbiprofen ve dekspantenolün oral topikal sulu farmasötik bileşimleri.
WO2016022700A8 (en) Tlr-independent small molecule adjuvants
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
UA112541C2 (uk) Застосування гідрохлориду амброксолу для лікування гострого фарингіту
WO2007138462A3 (en) Aqueous oral formulations of risperidone
ZA202100338B (en) Sweetening compositions

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20150901